Review 2021 - Record Sales

For the fifth year in a row, the Faubel Group increased its annual sales to 49 million euros, topping results in the previous year by 10 million. The group headquarters, Faubel & Co. Nachfolger GmbH in Melsungen, alone is accountable for 40 million euros..

"We cracked the 30 million euro mark for the first time in 2017. Just a few years later, we even scratched the 50 million euro mark!" explains Frank Jäger, one of Faubel's three CEOs. "We are incredibly grateful for this outstanding achievement and well aware that we cannot take it for granted."

To Frank Jäger, the steady growth of Faubel's market share in clinical trials is one key factor in this corporate success. Seventy-two percent of group sales originate from labels for drugs and vaccines that are still under test. "In research, time is money. Our customers like the fact that we can respond flexibly to their requirements. However, this is only possible because we keep investing in buildings and machinery and because we have such highly-committed staff."

New hires

In 2021, the Faubel Group hired ten new employees in various roles. At present, management is looking to fill eight additional positions. Prepress is to be staffed up, as are quality control and sales. According to early signs at the beginning of this year, the order situation is likely to remain stable. Therefore, we had to take on new staff. Although Frank Jäger does not expect 2022 to be another record year, "we still aim to validate our 2021 results. To achieve this, our employees need to stay safe. That is why we decided to maintain our hygiene, vaccination, and remote work schemes. The infection rate in-house is low, and of course, I would like to see that continue."